Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12619001352190
Ethics application status
Approved
Date submitted
24/09/2019
Date registered
1/10/2019
Date last updated
2/07/2021
Date data sharing statement initially provided
1/10/2019
Type of registration
Retrospectively registered

Titles & IDs
Public title
Comparative assessment of the absorption of a generic formulation of 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule against the innovator 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule conducted under fasting conditions in healthy male volunteers.
Scientific title
A single dose, randomized, open-label, pharmacokinetic study of a generic formulation of 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule in a 2 way crossover comparison against the innovator 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule conducted under fasting conditions in healthy male volunteers.
Secondary ID [1] 299008 0
None
Universal Trial Number (UTN)
U1111-1233-7386
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione is indicated for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. 314016 0
Condition category
Condition code
Blood 312405 312405 0 0
Other blood disorders
Cancer 313003 313003 0 0
Myeloma

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Single dose, crossover study design whereby each participant receives the test formulation of 25 mg 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule on one occasion and the innovator formulation of 25 mg 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione capsule on one occasion with each dose separated by a one week washout period. The intervention for this trial is the test capsule formulation.

No water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for the water consumed with each dose).

Participants are required not to eat for 10 hours before dosing and to fast for approximately 4 hours after each dose.

Bathroom visits will be supervised to ensure no unauthorized water or food intake and for personal safety.

Participants will be confined at the Clinical Site for 12 hours prior to dosing to ensure compliance and for 24 hours after dosing.

Participants will be monitored for adverse events throughout the study.

Standard meals will be consumed at the Clinical Site with no additional food intake allowed. Alcohol breath testing and dipstick drugs of abuse tests will be performed upon each participant reporting to the clinical site 12 hours prior to dosing.

Screening and study exit laboratory tests will be completed to assess the health of the participants along with HIV, Hepatitis and drugs of abuse testing.

Each dose will be taken orally with 240 ml of water at ambient temperature. Medication must be swallowed whole and a mouth check will be conducted to ensure that the medication has been taken as directed.
Intervention code [1] 315275 0
Treatment: Drugs
Comparator / control treatment
Single dose, crossover study whereby each participant receives the test formulation (1 x 25 mg) 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione on one occasion and the innovator formulation of (1 x 25 mg) 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione on one occasion with each dose separated by a one week washout period. The comparator/control for this trial is the innovator formulation.
Control group
Active

Outcomes
Primary outcome [1] 321053 0
To evaluate the pharmacokinetics (as summarised by Cmax and AUC) of the test formulation relative to that of the reference formulation. All plasma samples will be assayed for 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione using one fully validated LC/MS/MS method. Validation will be conducted to comply with FDA guidelines.
Timepoint [1] 321053 0
0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours post dosing.
Secondary outcome [1] 373809 0
Time to maximum peak concentration (Tmax) will be determined by plasma sample analysis. Tmax will be the time where the maximum concentration occurred in the sample points.
Timepoint [1] 373809 0
0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hours post dosing.

Eligibility
Key inclusion criteria
Healthy males
Aged between 18 and 55 years
Non-smoker
BMI greater than or equal to 18.5 and less than 30 inclusive
Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
Drug free as determined by urine drug testing
Able to comply with the study restrictions
Able to provide written informed consent
Minimum age
18 Years
Maximum age
55 Years
Sex
Males
Can healthy volunteers participate?
Yes
Key exclusion criteria
Females
Clinically significant medical conditions
History of conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
History of alcohol or drug abuse or dependency
Participation in a drug study within 30 days of the start of the study
Sensitivitie to the study drug or excipients
Individuals for whom the Clinical Investigator believes, for any reason, that participation would not be an acceptable risk

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All formulations will be labeled as Formulation A and B. The identification of each treatment will only be known to the Managing Director and Section Head - Trials and Regulatory Affairs or their delegate.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Each participant will be identified by a 3 digit screening number and a 2 digit subject number. The screening number will be issued once the participant has given written consent to participate in the study and the two digit study number (randomisation number) after acceptance into the study. Randomization will be performed using a randomisation table created by computer software (i.e. computerized sequence generation).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Bio-equivalence
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
5/10/2019
Actual
25/09/2019
Date of last participant enrolment
Anticipated
Actual
1/10/2019
Date of last data collection
Anticipated
Actual
14/10/2019
Sample size
Target
28
Accrual to date
Final
31
Recruitment outside Australia
Country [1] 21764 0
New Zealand
State/province [1] 21764 0
Otago

Funding & Sponsors
Funding source category [1] 303543 0
Commercial sector/Industry
Name [1] 303543 0
Luminarie Pty Ltd
Country [1] 303543 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Zenith Technology Corporation Limited
Address
PO Box 1777
Dunedin 9054
Country
New Zealand
Secondary sponsor category [1] 303613 0
None
Name [1] 303613 0
Address [1] 303613 0
Country [1] 303613 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 304071 0
Northern A Health and Disability Ethics Committee
Ethics committee address [1] 304071 0
Ethics committee country [1] 304071 0
New Zealand
Date submitted for ethics approval [1] 304071 0
05/06/2019
Approval date [1] 304071 0
04/07/2019
Ethics approval number [1] 304071 0
19/NTA/85

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 95722 0
Dr Noelyn Hung
Address 95722 0
Zenith Technology Corp Ltd
PO Box 1777,
Dunedin 9054
Country 95722 0
New Zealand
Phone 95722 0
+64 3 477 9669
Fax 95722 0
+6434779605
Email 95722 0
[email protected]
Contact person for public queries
Name 95723 0
Linda Folland
Address 95723 0
Zenith Technology Corp Ltd
PO Box 1777,
Dunedin 9054
Country 95723 0
New Zealand
Phone 95723 0
+64 3 477 9669
Fax 95723 0
+6434779605
Email 95723 0
[email protected]
Contact person for scientific queries
Name 95724 0
Tak Hung
Address 95724 0
Zenith Technology Corp Ltd
PO Box 1777,
Dunedin 9054
Country 95724 0
New Zealand
Phone 95724 0
+64 3 477 9669
Fax 95724 0
+6434779605
Email 95724 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
All data will be compiled into a final report that is the property of the sponsor company. All participant data will be provided in summary format and result of the study only will be reported


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.